Early High-volume Continuous Veno-venous Hemofiltration for Patients With Severe Acute Pancreatitis
NCT ID: NCT01595672
Last Updated: 2012-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
56 participants
INTERVENTIONAL
2012-04-30
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Continuous Blood Purification for Regulation of Early Inflammatory Response In Severe Acute Pancreatitis
NCT01998334
Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis
NCT02526303
Phase Ib of Recombinant Human Albumin Injection
NCT04701697
Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites
NCT06553456
RCA for CRRT in Liver Failure and High Risk Bleeding Patients
NCT03791190
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EHVCVVH group
Patients receive conventional treatments recommended by guidelines with adjunctive early high-volume continuous veno-venous hemofiltration (EHVCVVH).
AN69 hemofilter
An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.
Control group
Patients receive conventional treatments recommended by guidelines only.
conventional treatments
Patients receive conventional treatments recommended by guidelines only.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AN69 hemofilter
An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.
conventional treatments
Patients receive conventional treatments recommended by guidelines only.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* written informed consent
* Time from onset of abdominal pain to admission ≤ 72 hours
* SIRS score ≥ 2
Exclusion Criteria
* pregnancy
* patients needing emergency operation for abdominal compartment syndrome
* chronic renal diseases needing blood purification
* previous exploratory laparotomy for acute abdomen and diagnosis of pancreatitis during laparotomy
* acute flare-up of chronic pancreatitis
* malignancy
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Air Force Military Medical University, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qingchuan Zhao
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhao Qingchuan, PhD & MD
Role: PRINCIPAL_INVESTIGATOR
the First Affiliated Hospital of Fourth Military Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xijing Hospital of Digestive Diseases
Xi'an, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
81170432
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
SAP-CVVH-XHDD-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.